A Review of Genetic Alteration Correlated with Primary and Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer

Pritsana Raugrut; Jirapon Jirapongsak; Paramee Thongsuksai

doi:10.31584/jhsmr.20251199

A Review of Genetic Alteration Correlated with Primary and Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer

Pritsana Raugrut, Jirapon Jirapongsak, Paramee Thongsuksai

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly enhance both survival and quality of life for non-small cell lung cancer (NSCLC) patients with EGFR mutations. Nevertheless, an increasing number of patients exhibit primary or acquired resistance. Currently, discoveries of concurrent genetic alterations in EGFR and other genes besides EGFR have been made. Several studies have demonstrated an association between these alterations and resistance to EGFR-TKI. Therefore, it is crucial to gain more understanding of gene alterations and their impact on the effectiveness of EGFR-TKI treatment. In this review, concurrent gene alterations that can predict primary and acquired resistance to EGFR-TKIs in advanced NSCLC are discussed. This may assist clinicians in selecting the appropriate treatment for patients who have failed to respond to EGFR-TKIs.

Keywords

acquired resistance; EGFR-TKIs; genetic alteration; non-small cell lung cancer; primary resistance

Full Text:

PDF

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.

Rojanamatin J, Ukranun W, Supaattagorn P, Chaiwiriyabunya I, Wongsena M, Chaiwerawattana A, et al. Cancer in Thailand volume X 2016-2018. Bangkok: National Cancer Institute Ministry of Public Health; 2021.

Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic proceedings 2008;83:355-67.

Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today 2018;48:1-8.

Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 2022;15:94.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.

Sharma J, Shum E, Chau V, Paucar D, Cheng H, Halmos B. The evolving role of biomarkers in personalized lung cancer therapy. Respiration 2017;93:1-14.

Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res 2019;8(Suppl1):S23-47.

Ayoola A, Barochia A, Belani K, Belani CP. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012;30:433-46.

Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-60.

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol 2013;24:2080-7.

Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, et al. Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review. Front Oncol 2020;10:610923.

Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 2020;38:124-36.

Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther 2018;11:8575-87.

Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open 2020;5:e001011.

Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell RC, Altman RB, et al. PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenetics and genomics. 2013;23:636-42.

Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294-300.

Kaler AK, Patel K, Patil H, Tiwarekar Y, Kulkarni B, Hastak M, et al. Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma-An Indian Perspective of 212 Patients. Int J Environ Res Public Health 2022;20.

Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010;126:651-5.

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.

Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH, Gerber DE. Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR Inhibition. J Thorac Oncol 2015;10:e86-8.

Zubair T, Bandyopadhyay D. Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci 2023;24.

Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules (Basel, Switzerland) 2021;26.

Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future oncology (London, England) 2018;14:1117-32.

Simasi J, Schubert A, Oelkrug C, Gillissen A, Nieber K. Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer. Anticancer Res 2014;34:2841-50.

Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer 2017;106:17-21.

Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, et al. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget 2016;7:36311-20.

Jin Y, Shi X, Zhao J, He Q, Chen M, Yan J, et al. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer 2018;124:110-6.

Xu Y, Tong X, Yan J, Wu X, Shao YW, Fan Y. Short-Term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms. Transl Oncol 2018;11:1364-9.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, et al. Genetic profiling of non-small cell lung cancer at development of resistance to first- or second-generation EGFR-TKIs by CAPP-Seq analysis of circulating tumor DNA. The Oncologist 2019;24:1022-6.

Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, et al. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer 2017;113:106-14.

Chua KP, Teng YHF, Tan AC, Takano A, Alvarez JJS, Nahar R, et al. Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities. Clin Cancer Res 2021;27:5939-50.

Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, et al. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 2016;7:61755-63.

Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2013;82:109-14.

Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89.

Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget 2017;8:1343-53.

DOI: http://dx.doi.org/10.31584/jhsmr.20251199

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.